Corbus Pharmaceuticals announces first patient dosed with its Nectin-4 targeting ADC CRB-701 in combination with pembrolizumab

CAR-T Digest - August 2020

25 June 2025: Corbus Pharmaceuticals announces first patient dosed with its Nectin-4 targeting ADC CRB-701 in combination with pembrolizumab

Corbus Pharmaceuticals has dosed the first participant in the PD-1 combination arm of its Phase 1 Western study of CRB-701 in solid tumors, with patients receiving 2.7 mg/kg or 3.6 mg/kg doses combined with Keytruda
The Phase 1 trial evaluates CRB-701 in solid tumors with high Nectin-4 expression across three parts: dose escalation, optimization, and expansion
Initial data show promising safety, tolerability, and efficacy of CRB-701 in head and neck squamous cell carcinoma (HNSCC), cervical cancer, and metastatic urothelial carcinoma (mUC)
The study is expected to identify a recommended Phase 2 dose (RP2D) and provide a data update in Q4 2025